Seamus Fernandez's Stock Ratings

Guggenheim Analyst

Seamus Fernandez is an analyst at Guggenheim. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/14/2024

Overall Average Return

15.3%

Smart Score

68.2%

Overall Average Return Percentile

72nd

Number of Ratings

30
No data available to display
date
▲▼
ticker
▲▼
Buy Now
Company
▲▼
Current price
▲▼
Upside/Downside
▲▼
Analyst Firm
▲▼
Analyst & % Accurate
▲▼
Price Target Change
▲▼
Rating Change
▲▼
Previous / Current Rating
▲▼
Get Alert

Recent Analyst Stock Rating News

Arcturus Therapeutics Stock Is Rising Wednesday: What's Going On?
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) shares are trading higher Wednesday after the company reported strong fourth-quarter results and provided an update on pipeline progress.
Failure Of This Merck Study Is A 'Material Risk' But Analysts Are 'Extremely Bullish'
Merck & Co. Inc. (NYSE: MRK) seems well positioned to surpass 2023 consensus estimates, driven by margin potential, according to Guggenheim. The Analyst: Seamus Fernandez upgraded the rating for Merck from Neutral to Buy, while establishing a price target of $104.
Bristol-Myers Squibb Analyst Sees Multiple Expansion Story, Limited Near-Term Downside Risk
An analyst at Guggenheim Securities turned bullish on pharma giant Bristol-Myers Squibb Co (NYSE: BMY) Monday, basing their optimism on a revival in sales of its flagship immuno-oncology drug Opdivo.
Intense Competition Pressures Eli Lilly, Leerink Downgrades
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
The Best BioPharma Plays Amid Uncertainty From Trump Comments
Tesaro Shares Lower On Receipt Of FDA Complete Response Letter
Why The Amgen/Regeneron Patent Saga Is Far From Over
Argus: Bristol-Myers Selloff Is Overdone, Reiterating $90 Target
Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free